IONTAS and IGEM Collaborate to Find Novel IgE Antibodies for Cancer Treatment

IONTAS and IGEM Collaborate to Find Novel IgE Antibodies for Cancer Treatment
The development of novel IgE antibodies targeting solid tumors will receive a boost following a new collaboration between IONTAS and IGEM Therapeutics. IGEM is an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. The collaboration will add to IGEM’s pipeline of therapies and expand upon IGEM-F, an IgE antibody targeting ovarian and other cancers that is already being tested in a Phase 1 clinical trial (NCT02546921). IONTAS is a biotechnology company focused on antibody discovery. Under this collaboration, IONTAS will use its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets. Unlike immunoglobulin G (IgG), IgE antibodies have ideal features for the treatment of solid tumors. IgE antibodies inflitrate tumor tissue more effectively, exhibit enhanced effector functions (meaning the antibodies have an increased ability to trigger a response from T-cells), and induce greater levels of cytotoxicity and phagocytosis (meaning they may trigger a more powerful immune response to tumor cells than the currently available IgG antibodies). “This collaboration capitalizes on the antibody discovery capabilities at IONTAS which enable the generation of high-quality therapeutic antibodies using phage-display or mammalian-display,” John McCafferty, chief executive officer at IONTAS, said in a press release<
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *